Assertio Holdings, Inc. (ASRT)
Automate Your Wheel Strategy on ASRT
With Tiblio's Option Bot, you can configure your own wheel strategy including ASRT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ASRT
- Rev/Share 1.2201
- Book/Share 0.9722
- PB 0.7998
- Debt/Equity 0.4185
- CurrentRatio 1.5861
- ROIC -0.2643
- MktCap 74826289.0
- FreeCF/Share 0.1882
- PFCF 4.1418
- PE -1.748
- Debt/Assets 0.1426
- DivYield 0
- ROE -0.3766
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
NASDAQ: SPPI CLASS ACTION NOTICE: Berger Montague Encourages Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action
Published: August 19, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
SHAREHOLDER ALERT: Berger Montague Reminds Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of Class Action Lawsuit Deadline
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Aug. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).
Read More
NASDAQ: SPPI INVESTOR ALERT: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of September 24, 2025 Deadline
Published: August 13, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 13, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).
Read More
Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Aug. 6, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Read More
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio” or the “Company”) common stock issued in exchange for Spectrum Pharmaceuticals, Inc. (“Spectrum”) common stock in connection with Assertio's July 31, 2023 merger with Spectrum (the “Merger”), charging the Company and certain of its current and former senior executives and directors with violations of the federal securities laws (collectively, “Defendants”).
Read More
About Assertio Holdings, Inc. (ASRT)
- IPO Date 1997-12-03
- Website https://www.assertiotx.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Brendan P. O'Grady
- Employees 58